Literature DB >> 37593

Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.

K Dornbusch, C E Nord, B Olsson-Liljeqvist.   

Abstract

It was shown that recent Swedish clinical isolates of anaerobic bacteria are susceptible to many antibiotics by the agar dilution method with the exception of the Bacteroides group versus beta-lactam antibiotics or tetracyclines. Strains of B. fragilis were inhibited by 4--greater than 128 micrograms benzylpenicillin or cephalothin/ml, 1.0--64 micrograms cefoxitin/ml, 0.064--2 micrograms clindamycin or metronidazole/ml, 2--8 micrograms chloramphenicol/ml, 2--16 micrograms fusidic acid/ml and 0.032--32 micrograms doxycycline/ml. Resistance to beta-lactam antibiotics was partly due to the production of beta-lactamase. Growth of beta-lactamase producing strains in the presence of enzyme inhibitors such as clavulanic acid or CP-45899 together with cephaloridine lowered the MIC's manyfold. Cefoxitin with relative resistance to beta-lactamases inhibited the majority of the strains at 8 micrograms/ml. Cefoxitin-resistant strains (MIC greater than or equal to 16 micrograms/ml) were also resistant to the new cephalosporins BL-S786 and HR-756 as well as to the new cefamycins A, B, CL619-183, CS-1170 and Sq-14359 and to thienamycin. Cefamycin CL619-183, only showed a slightly higher in vitro activity than cefoxitin. Resistance to the cefamycins could not be correlated to the production of beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37593

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  22 in total

1.  In vitro activity of L-627 against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  Susceptibility of anaerobic bacteria to PD 131628.

Authors:  C E Nord; A Hagelbäck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

3.  Comparative in vitro activity of the new oral cephalosporin Bay v 3522 against aerobic and anaerobic bacteria.

Authors:  M Rylander; C E Nord; S R Norrby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

4.  Susceptibility of anaerobic bacteria to BAY v 3522.

Authors:  C E Nord; M Rylander; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Susceptibility of anaerobic bacteria to tosufloxacin.

Authors:  C E Nord; A Lindmark; I Persson; C Runow
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

6.  Susceptibility of anaerobic bacteria to ALP 201.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

7.  Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

8.  Susceptibility of Clostridium difficile to LY146032.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

9.  Susceptibility of anaerobic bacteria to FCE 22101.

Authors:  C E Nord; A Lindmark; I Person
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

10.  In vitro activity of DMG-Mino and DMG-DM Dot, two new glycylcyclines, against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.